Literature DB >> 25579549

Investigation on immune function and chest drainage in patients with thoracic malignancies using the streptococcal agent Sapylin.

Kaihua Tian1, Bin Han, Yi Shen, Chuan Li, Yunpeng Xuan.   

Abstract

PURPOSE: To investigate the influence of Sapylin used during the operation on immune function and chest drainage in patients with thoracic malignancies in early postoperative period. PATIENTS AND METHODS: Seventy-one patients with thoracic malignancies including lung cancer and esophageal carcinoma who underwent tumor resection were divided into two groups, 36 cases of observation group and 35 cases of control group. In observation group, Sapylin were locally laid in operation field during the operation. The control group was not given Sapylin. Drainage volume of chest cavity after operation, and the levels of CD4, CD8, CD4/CD8 and natural killer (NK) cell were recorded.
RESULTS: The level of CD4+, CD4+/CD8+ and NK cell in observation group were higher than that in control group (P<0.05) wholly in early postoperative period. Drainage volume of chest cavity in observation group was less than that in control group postoperatively, 1160.2±437.2 ml vs. 1363.3±472.9 ml, but the change in two groups had no significance statistically (P=0.064).
CONCLUSIONS: The local application of Sapylin during operation can improve immunity of patients with thoracic malignancies significantly and decrease the drainage volume of chest cavity probably in early postoperative period. So it is worthy of popularizing in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25579549     DOI: 10.4103/0973-1482.137983

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  1 in total

1.  Effects of programmed death-ligand 1 expression on OK-432 immunotherapy following transurethral resection in non-muscle invasive bladder cancer.

Authors:  Zhi-Hua Liu; Fu-Fu Zheng; Yu-Ling Mao; Lie-Fu Ye; Jun Bian; De-Hui Lai; Yun-Lin Ye; Yu-Ping Dai
Journal:  Oncol Lett       Date:  2017-04-24       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.